NCT05537896View on ClinicalTrials.gov

Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

February 19, 2024

Primary Completion Date

February 29, 2028

Study Completion Date

February 29, 2028

Conditions
Hematological MalignancyNeutropenia
Interventions
DRUG

Eravacycline

"Eravacycline will be continued until one of the following criteria is met:~* neutrophil recovery (ANC \>500, post-nadir)~* febrile neutropenia~* breakthrough infection~* any grade 3-4 toxicity related to eravacycline use~* 21 days of therapy (maximum duration allowed per study protocol)"

Trial Locations (1)

26506

RECRUITING

Aaron Cumpston, Morgantown

All Listed Sponsors
lead

West Virginia University

OTHER